## **Mical Paul**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8290319/publications.pdf Version: 2024-02-01

		25014	18115
211	15,974	57	120
papers	citations	h-index	g-index
213	213	213	19086
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	InÂvivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections. Clinical Microbiology and Infection, 2022, 28, 73-78.	2.8	1
2	Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies. Clinical Infectious Diseases, 2022, 75, 1081-1084.	2.9	41
3	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq1 1	0.78.48314	ŀrg <b>₿ī⊵</b> ∦Overlo
4	A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	9
5	Effectiveness and safety of colistin among older adults: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2022, 77, 2094-2104.	1.3	4
6	Is shorter always better? The pros and cons of treating Gram-negative bloodstream infections with 7 days of antibiotics. JAC-Antimicrobial Resistance, 2022, 4, .	0.9	2
7	Predicting In-Hospital Antibiotic Use in the Medical Department: Derivation and Validation Study. Antibiotics, 2022, 11, 813.	1.5	0
8	The Effect of β-Blockers for Burn Patients on Clinical Outcomes: Systematic Review and Meta-Analysis. Journal of Intensive Care Medicine, 2021, 36, 945-953.	1.3	6
9	Oral Capsulized Fecal Microbiota Transplantation for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization With a Metagenomic Perspective. Clinical Infectious Diseases, 2021, 73, e166-e175.	2.9	33
10	Integration of FDG-PET/CT in the Diagnostic Workup for <i>Staphylococcus aureus</i> Bacteremia: A Prospective Interventional Matched-cohort Study. Clinical Infectious Diseases, 2021, 73, e3859-e3866.	2.9	28
11	Investigator-initiated Randomized Controlled Trials in Infectious Diseases: Better Value for Money for Registration Trials of New Antimicrobials. Clinical Infectious Diseases, 2021, 72, 1259-1264.	2.9	4
12	Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2021, 27, 341-351.	2.8	69
13	Efficacy of βâ€lactam/βâ€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing <i>Enterobacterales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€6OT Project). Transplant Infectious Disease, 2021, 23, e13520.	0.7	10
14	Reporting of systematic reviews and meta-analysis of observational studies. Clinical Microbiology and Infection, 2021, 27, 311-314.	2.8	11
15	Has the door closed on hydroxychloroquine for SARS-COV-2?. Clinical Microbiology and Infection, 2021, 27, 3-5.	2.8	6
16	Treatment of Bacteremia Caused by Enterobacter spp.: Should the Potential for AmpC Induction Dictate Therapy? A Retrospective Study. Microbial Drug Resistance, 2021, 27, 410-414.	0.9	5
17	Antibiotic stewardship in the emergency department: not to be overlooked. Clinical Microbiology and Infection, 2021, 27, 172-174.	2.8	2
18	Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open, 2021, 11, e040210.	0.8	10

#	Article	IF	CITATIONS
19	Abandoned trials in infection diseases and clinical microbiology: a call for action. Clinical Microbiology and Infection, 2021, 27, 501-502.	2.8	Ο
20	A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. Clinical Microbiology and Infection, 2021, 27, 1746-1753.	2.8	5
21	Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda. International Journal of Antimicrobial Agents, 2021, 57, 106320.	1.1	6
22	Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries. Journal of Antimicrobial Chemotherapy, 2021, 76, 1614-1624.	1.3	60
23	Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2172-2181.	1.3	19
24	The Role of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Management of Nocardiosis: A Retrospective Study and Review of the Literature. Infectious Diseases and Therapy, 2021, 10, 2227-2246.	1.8	5
25	Predictors of Readmission Following Discharge of Patients With Gram-Negative Bacteremia: A Retrospective Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab373.	0.4	3
26	Screening for Q Fever in Patients Undergoing Transcatheter Aortic Valve Implantation, Israel, June 2018–May 2020. Emerging Infectious Diseases, 2021, 27, 2205-2207.	2.0	1
27	InadequateÂreporting of participants eligible for randomized controlled trials – A Systematic Review and Meta-Analysis Journal of Clinical Epidemiology, 2021, 140, 125-134.	2.4	1
28	Repurposed drugs for COVID-19: threshold and proof requirements for trials. Clinical Microbiology and Infection, 2021, 27, 1716-1717.	2.8	3
29	EMBRACE-WATERS statement: Recommendations for reporting of studies on antimicrobial resistance in wastewater and related aquatic environments. One Health, 2021, 13, 100339.	1.5	11
30	The Impact of Nosocomial Bloodstream Infections on Mortality: A Retrospective Propensity-Matched Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab552.	0.4	3
31	Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study. PLoS ONE, 2021, 16, e0259707.	1.1	1
32	Reply to De Greef et al. Clinical Infectious Diseases, 2020, 70, 351-353.	2.9	2
33	Reply to Nucci. Clinical Infectious Diseases, 2020, 70, 347-349.	2.9	3
34	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clinical Infectious Diseases, 2020, 70, 2270-2280.	2.9	24
35	Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients. Age and Ageing, 2020, 49, 26-31.	0.7	11
36	Early diagnosis of bloodstream infections in the intensive care unit using machine-learning algorithms. Intensive Care Medicine, 2020, 46, 454-462.	3.9	41

#	Article	IF	CITATIONS
37	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. American Journal of Transplantation, 2020, 20, 1629-1641.	2.6	17
38	Reply to Wilson et al. Clinical Infectious Diseases, 2020, 71, 1358-1359.	2.9	0
39	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clinical Infectious Diseases, 2020, 71, 2599-2607.	2.9	10
40	Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. International Journal of Antimicrobial Agents, 2020, 55, 105847.	1.1	33
41	Direct on-the-spot detection of SARS-CoV-2 in patients. Experimental Biology and Medicine, 2020, 245, 1187-1193.	1.1	33
42	Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. Open Forum Infectious Diseases, 2020, 7, ofaa461.	0.4	41
43	Long-term consequences of COVID-19: research needs. Lancet Infectious Diseases, The, 2020, 20, 1115-1117.	4.6	241
44	Considerations for the optimal management of antibiotic therapy in elderly patients. Journal of Global Antimicrobial Resistance, 2020, 22, 325-333.	0.9	27
45	Critical analysis of antibacterial agents in clinical development. Nature Reviews Microbiology, 2020, 18, 286-298.	13.6	204
46	Are corticosteroids or end-stage renal failure associated with an afebrile presentation of Gram-negative bacteraemia?. International Journal of Antimicrobial Agents, 2020, 56, 106070.	1.1	1
47	Comparison of antibiotic-resistant bacteria and antibiotic resistance genes abundance in hospital and community wastewater: A systematic review. Science of the Total Environment, 2020, 743, 140804.	3.9	126
48	Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia. JAMA - Journal of the American Medical Association, 2020, 323, 527.	3.8	169
49	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: inÂvitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	2.8	46
50	White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in long-term care facilities—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. Journal of Antimicrobial Chemotherapy, 2020, 75, ii33-ii41.	1.3	7
51	A Protocol for Simple, Rapid, and Direct Detection of SARS-CoV-2 from clinical samples, using Reverse Transcribed Loop-Mediated Isothermal Amplification (RT-LAMP). Bio-protocol, 2020, 10, e3789.	0.2	0
52	Meta-analysis of Polymyxin Use in Patients. Advances in Experimental Medicine and Biology, 2019, 1145, 143-153.	0.8	1
53	Risk factors for meningitis in neurosurgical patients with cerebrospinal fluid drains: prospective observational cohort study. Acta Neurochirurgica, 2019, 161, 517-524.	0.9	42
54	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiâ€infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy, 2019, 39, 10-39.	1.2	545

#	Article	IF	CITATIONS
55	Trimethoprim-sulfamethoxazole vs. colistin or ampicillin–sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study. Journal of Global Antimicrobial Resistance, 2019, 17, 168-172.	0.9	14
56	Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients: A Prospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 1805-1808.	2.9	22
57	β-lactam antibiotics vs. vancomycin for the early treatment of enterococcal bacteraemia: A retrospective cohort study. International Journal of Antimicrobial Agents, 2019, 53, 761-766.	1.1	3
58	The association of vancomycin trough levels with outcomes among patients with methicillin-resistant Staphylococcus aureus (MRSA) infections: Retrospective cohort study. PLoS ONE, 2019, 14, e0214309.	1.1	5
59	Reply to MacFadden and Hanage and to Pallett et al. Clinical Infectious Diseases, 2019, 69, 1263-1264.	2.9	0
60	Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clinical Infectious Diseases, 2019, 69, 1091-1098.	2.9	256
61	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clinical Infectious Diseases, 2019, 69, 769-776.	2.9	83
62	Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clinical Infectious Diseases, 2019, 69, 1731-1739.	2.9	29
63	Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infectious Diseases, The, 2019, 19, e40-e50.	4.6	161
64	Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. Clinical Infectious Diseases, 2019, 68, 1691-1698.	2.9	42
65	Risk factors for mortality among carbapenem-resistant enterobacteriaceae carriers with focus on immunosuppression. Journal of Infection, 2019, 78, 101-105.	1.7	11
66	Reemergence of Human Brucellosis in Israel. Israel Medical Association Journal, 2019, 21, 10-12.	0.1	8
67	Colistin versus colistin plus meropenem for severe infections Authors' reply. Lancet Infectious Diseases, The, 2018, 18, 495-496.	4.6	1
68	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	4.6	400
69	Association between human brucellosis and adverse pregnancy outcome: a cross-sectional population-based study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 883-888.	1.3	4
70	Secular trends in the appropriateness of empirical antibiotic treatment in patients with bacteremia: a comparison between three prospective cohorts. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 455-462.	1.3	7
71	Determinants of inappropriate empirical antibiotic treatment: systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2018, 51, 548-553.	1.1	50
72	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 318-327.	4.6	3,672

#	Article	IF	CITATIONS
73	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. Clinical Infectious Diseases, 2018, 67, 1815-1823.	2.9	29
74	β-lactam prolonged infusion: it's time to implement!. Lancet Infectious Diseases, The, 2018, 18, 13-14.	4.6	2
75	Slowly Evolving Brain Abscess Caused by Nocardia beijingensis in a Kidney Transplant Patient. Infectious Diseases in Clinical Practice, 2018, 26, 369-370.	0.1	3
76	Risk factors for limb surgical site infection following coronary artery bypass graft using open great saphenous vein harvesting: a retrospective cohort study. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 530-535.	0.5	8
77	Legal framework of antimicrobial stewardship in hospitals (LEASH): a European Society of Clinical Microbiology and Infectious Diseases (ESCMID) cross-sectional international survey. International Journal of Antimicrobial Agents, 2018, 52, 616-621.	1.1	8
78	Replacement of Urinary Catheter for Urinary Tract Infections: A Prospective Observational Study. Journal of the American Geriatrics Society, 2018, 66, 1779-1784.	1.3	11
79	Microbiota manipulation for weight change. Microbial Pathogenesis, 2017, 106, 146-161.	1.3	63
80	Clinical presentation, management and outcomes of Staph aureus bacteremia (SAB) in older adults. Aging Clinical and Experimental Research, 2017, 29, 127-133.	1.4	12
81	Automatic learning of mortality in a CPN model of the systemic inflammatory response syndrome. Mathematical Biosciences, 2017, 284, 12-20.	0.9	16
82	Urinary Tract Infections Due to Nontyphoidal Salmonella. American Journal of the Medical Sciences, 2017, 353, 529-532.	0.4	12
83	Revival of old antibiotics: needs, the state of evidence and expectations. International Journal of Antimicrobial Agents, 2017, 49, 536-541.	1.1	40
84	Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary Tract Infection: Prospective Cohort Study. Clinical Infectious Diseases, 2017, 65, 1799-1805.	2.9	35
85	Time trends in Staphylococcus aureus bacteremia, 1988–2010, in a tertiary center with high methicillin resistance rates. Infection, 2017, 45, 51-57.	2.3	6
86	Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2017, 72, 29-39.	1.3	136
87	Addressing resistance to antibiotics in systematic reviews of antibiotic interventions. Journal of Antimicrobial Chemotherapy, 2016, 71, 2367-2369.	1.3	45
88	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	0.8	41
89	Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures. Antimicrobial Agents and Chemotherapy, 2016, 60, 4717-4721.	1.4	24
90	Comparison of Antibiotic Susceptibility Patterns of Bacterial Isolates Based on Time From Hospitalization and Culture Source: Implications for Hospital Antibiograms. Infection Control and Hospital Epidemiology, 2016, 37, 212-214.	1.0	3

#	Article	IF	CITATIONS
91	Rate of colonization of health care workers by carbapenem-resistant Enterobacteriaceae in an endemic hospital: A prospective study. American Journal of Infection Control, 2016, 44, 1053-1054.	1.1	6
92	The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study. Clinical Infectious Diseases, 2016, 63, 1605-1612.	2.9	45
93	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09â€related pneumonia: an individual participant data metaâ€analysis. Influenza and Other Respiratory Viruses, 2016, 10, 192-204.	1.5	54
94	Management of Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2016, 316, 220.	3.8	0
95	<i>Campylobacter</i> bacteraemia: 16 years of experience in a single centre. Infectious Diseases, 2016, 48, 796-799.	1.4	22
96	Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 2729-2739.	1.3	132
97	Antibiotic treatment: balancing patients' rights. Lancet Respiratory Medicine,the, 2016, 4, 10-11.	5.2	0
98	Diagnostic Accuracy of PCR Alone and Compared to Urinary Antigen Testing for Detection of Legionella spp.: a Systematic Review. Journal of Clinical Microbiology, 2016, 54, 401-411.	1.8	58
99	High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia. Acta Haematologica, 2016, 135, 55-64.	0.7	8
100	Bloodstream infections in older patients. Virulence, 2016, 7, 341-352.	1.8	44
101	Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0129305.	1.1	212
102	Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ, The, 2015, 350, h2219-h2219.	3.0	112
103	Interpretative reading of the antibiogram – a semi-naÃ⁻ve Bayesian approach. Artificial Intelligence in Medicine, 2015, 65, 209-217.	3.8	8
104	The association between infections and chemotherapy interruptions among cancer patients: Prospective cohort study. Journal of Infection, 2015, 70, 223-229.	1.7	18
105	The association of central venous catheter placement timing with infection rates in patients with acute leukemia. Leukemia Research, 2015, 39, 311-313.	0.4	4
106	Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2015, 70, 979-996.	1.3	58
107	Participation of Elderly Adults in Randomized Controlled Trials Addressing Antibiotic Treatment of Pneumonia. Journal of the American Geriatrics Society, 2015, 63, 233-243.	1.3	19
108	Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2015, 46, 242-248.	1.1	45

#	Article	IF	CITATIONS
109	Reviving old antibiotics. Journal of Antimicrobial Chemotherapy, 2015, 70, 2177-2181.	1.3	79
110	Presentation of infection in older patients—a prospective study. Annals of Medicine, 2015, 47, 354-358.	1.5	13
111	Risk Factors for Recurrence of Carbapenem-Resistant Enterobacteriaceae Carriage: Case-Control Study. Infection Control and Hospital Epidemiology, 2015, 36, 936-941.	1.0	39
112	Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2015, 70, 3146-3153.	1.3	53
113	External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA. BMJ Open, 2015, 5, e008838.	0.8	18
114	β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2015, 70, 41-47.	1.3	40
115	Cochrane Column. International Journal of Epidemiology, 2014, 43, 1691-1696.	0.9	1
116	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respiratory Medicine,the, 2014, 2, 395-404.	5.2	527
117	Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hematoâ€oncological patients: Randomized controlled trial. American Journal of Hematology, 2014, 89, 243-248.	2.0	16
118	Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. , 2014, , CD003914.		17
119	Combination therapy for carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2014, 69, 2305-2309.	1.3	179
120	Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation. Journal of Infection, 2013, 67, 194-198.	1.7	9
121	Systematic Review and Meta-Analysis of <i>In Vitro</i> Synergy of Polymyxins and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 5104-5111.	1.4	202
122	Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica, 2013, 98, 95-102.	1.7	31
123	Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection— 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2013, 68, 2183-2191.	1.3	111
124	The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. Leukemia Research, 2013, 37, 1057-1062.	0.4	20
125	Time to first antibiotic dose for patients hospitalised with community-acquired pneumonia. International Journal of Antimicrobial Agents, 2013, 41, 410-413.	1.1	23
126	Editorial Commentary: Combination Therapy for Pseudomonas aeruginosa Bacteremia: Where Do We Stand?. Clinical Infectious Diseases, 2013, 57, 217-220.	2.9	32

#	Article	IF	CITATIONS
127	A breach in patients' safety in randomized controlled trials of antibiotic drugs. Journal of Antimicrobial Chemotherapy, 2013, 68, 2179-2180.	1.3	4
128	Long-term survival in patients included in a randomized controlled trial of TREAT, a decision support system for antibiotic treatment. Journal of Antimicrobial Chemotherapy, 2013, 68, 2664-2666.	1.3	22
129	Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer, 2013, 119, 4028-4035.	2.0	34
130	Diagnostic Accuracy of PCR Alone Compared to Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis: a Systematic Review. Journal of Clinical Microbiology, 2012, 50, 3652-3658.	1.8	113
131	Ethical dilemmas in antibiotic treatment. Journal of Antimicrobial Chemotherapy, 2012, 67, 12-16.	1.3	50
132	Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2012, 67, 541-550.	1.3	117
133	Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. International Journal of Antimicrobial Agents, 2012, 40, 123-126.	1.1	19
134	Does Sex Affect 30-Day Mortality in Staphylococcus Aureus Bacteremia?. Gender Medicine, 2012, 9, 463-470.	1.4	24
135	Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microbial Pathogenesis, 2012, 53, 100-108.	1.3	364
136	Elevation of CRP Precedes Bloodstream Infections in Patients Undergoing Hematopoietic Cell Transplantation – a Case-Control Study Blood, 2012, 120, 3026-3026.	0.6	0
137	Thrombocytopenia in Staphylococcus aureus Bacteremia: Risk Factors and Prognostic Importance. Mayo Clinic Proceedings, 2011, 86, 389-396.	1.4	63
138	Clinical implications of β-lactam–aminoglycoside synergism: systematic review of randomised trials. International Journal of Antimicrobial Agents, 2011, 37, 491-503.	1.1	67
139	A model for diagnosis of pulmonary infections in solid-organ transplant recipients. Computer Methods and Programs in Biomedicine, 2011, 104, 135-142.	2.6	8
140	Commentary on â€~Antiâ€pseudomonal betaâ€lactams for the initial, empirical, treatment of febrile neutropenia: comparison of betaâ€lactams' with a response from the review authors. Evidence-Based Child Health: A Cochrane Review Journal, 2011, 6, 2188-2191.	2.0	1
141	Infections in Hematogical Cancer Patients: The Contribution of Systematic Reviews and Meta-Analyses. Acta Haematologica, 2011, 125, 80-90.	0.7	5
142	Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1150-1155.	1.3	66
143	PCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis. Journal of Clinical Microbiology, 2011, 49, 665-670.	1.8	309
144	Efficacy and safety of tigecycline: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2011, 66, 1963-1971.	1.3	234

#	Article	IF	CITATIONS
145	The Role of PET-CT for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Febrile Neutropenia. Blood, 2011, 118, 4289-4289.	0.6	0
146	Odds ratios are contingent on event rates. Critical Care Medicine, 2010, 38, 2425-2426.	0.4	1
147	Management of adult patients with acute lymphoblastic leukemia in first complete remission. Cancer, 2010, 116, 3447-3457.	2.0	70
148	Cochrane review: Oral iron supplementation for preventing or treating anaemia among children in malariaâ€endemic areas. Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 967-1183.	2.0	2
149	Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy, 2010, 65, 2658-2665.	1.3	184
150	Metaâ€analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use. Clinical Infectious Diseases, 2010, 51, 1350-1351.	2.9	14
151	Catheter Extraction Does Not Improve Survival in Candidemia, or Does It?. Clinical Infectious Diseases, 2010, 51, 1347-1348.	2.9	4
152	Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2010, 65, 1779-1783.	1.3	47
153	Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis. Antimicrobial Agents and Chemotherapy, 2010, 54, 4851-4863.	1.4	578
154	Excess mortality related to cefepime. Lancet Infectious Diseases, The, 2010, 10, 293-294.	4.6	11
155	Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. The Cochrane Library, 2010, , CD005197.	1.5	41
156	Effectiveness and safety of colistin: prospective comparative cohort study. Journal of Antimicrobial Chemotherapy, 2010, 65, 1019-1027.	1.3	135
157	PCR Using Blood for Diagnosis of Invasive Pneumococcal Disease: Systematic Review and Meta-Analysis. Journal of Clinical Microbiology, 2010, 48, 489-496.	1.8	67
158	Hematopoietic Growth Factors In Aplastic Anemia Patients Treated with Immunosuppressive Therapy: Systematic Review and Meta-Analysis - 2010 Update Blood, 2010, 116, 1164-1164.	0.6	0
159	Anthracycline-Containing Regimens for Treatment of Follicular Lymphoma In Adults: Systematic Review and Meta-Analysis Blood, 2010, 116, 2820-2820.	0.6	1
160	Learning Susceptibility of a Pathogen to Antibiotics Using Data from Similar Pathogens. Methods of Information in Medicine, 2009, 48, 242-247.	0.7	3
161	Predictors for anaerobic bacteraemia beyond the source of infection: Retrospective, nested, case-control study. Scandinavian Journal of Infectious Diseases, 2009, 41, 33-36.	1.5	4
162	Reply to N. Reddy et al. Journal of Clinical Oncology, 2009, 27, 2297-2298.	0.8	1

#	Article	IF	CITATIONS
163	Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica, 2009, 94, 712-719.	1.7	74
164	Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis. Antimicrobial Agents and Chemotherapy, 2009, 53, 4069-4079.	1.4	239
165	Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. Journal of Antimicrobial Chemotherapy, 2009, 64, 239-250.	1.3	50
166	Immunoglobulin Prophylaxis in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2009, 27, 770-781.	0.8	140
167	Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens. Journal of Antimicrobial Chemotherapy, 2009, 63, 400-404.	1.3	22
168	Cefepime and All ause Mortality. Clinical Infectious Diseases, 2009, 49, 640-641.	2.9	4
169	Aminoglycoside drugs in clinical practice: an evidence-based approach. Journal of Antimicrobial Chemotherapy, 2009, 63, 246-251.	1.3	75
170	Duration of antibiotic prophylaxis for cardiac surgery: Prospective observational study. Journal of Infection, 2009, 58, 291-298.	1.7	11
171	Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leukemia and Lymphoma, 2009, 50, 764-772.	0.6	125
172	Combination Antimicrobial Treatment Versus Monotherapy: The Contribution of Meta-analyses. Infectious Disease Clinics of North America, 2009, 23, 277-293.	1.9	42
173	Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 97-107.	4.6	61
174	Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis Blood, 2009, 114, 49-49.	0.6	10
175	Myeloid Colony-Stimulating Factors Do Not Increase the Risk of Mortality or Disease Activity Measures in Patients with Acute Myeloid Leukemia: Systematic Review and Meta-Analysis Blood, 2009, 114, 2045-2045.	0.6	1
176	The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Neutropenia and Fever Blood, 2009, 114, 3121-3121.	0.6	0
177	Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. Journal of Infection, 2008, 57, 236-240.	1.7	12
178	Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2008, 52, 897-906.	2.1	147
179	ATG plus Cyclosporine Reduces All-Cause Mortality in Patients with Severe Aplastic Anemia – Systematic Review and Meta-Analysis. Acta Haematologica, 2008, 120, 237-243.	0.7	24
180	Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2008, 83, 1011-1021.	1.4	87

#	Article	IF	CITATIONS
181	Antimicrobial Lock Solutions for the Prevention of Infections Associated with Intravascular Catheters in Patients Undergoing Hemodialysis: Systematic Review and Metaâ€analysis of Randomized, Controlled Trials. Clinical Infectious Diseases, 2008, 47, 83-93.	2.9	255
182	ATG Plus Cyclosporine-a Should Be Used as Immunosuppressive Therapy in Patients with Severe Aplastic Anemia-Systematic Review and Meta-Analysis. Blood, 2008, 112, 4120-4120.	0.6	0
183	Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. Journal of Antimicrobial Chemotherapy, 2007, 59, 1204-1207.	1.3	29
184	Propensityâ€Matched Analysis of Appropriate Empirical Antibiotic Treatment. Clinical Infectious Diseases, 2007, 44, 1251-1252.	2.9	7
185	Appropriateness of antibiotic therapy on weekends versus weekdays. Journal of Antimicrobial Chemotherapy, 2007, 60, 625-628.	1.3	14
186	Aminoglycoside/Â-lactam combinations in clinical practice. Journal of Antimicrobial Chemotherapy, 2007, 60, 911-912.	1.3	10
187	Vancomycin and Metronidazole for the Treatment of Clostridium difficileAssociated Diarrhea. Clinical Infectious Diseases, 2007, 45, 1646-1647.	2.9	8
188	Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2007, 7, 338-348.	4.6	233
189	Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2007, 60, 247-257.	1.3	130
190	Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clinic Proceedings, 2007, 82, 1052-1059.	1.4	335
191	The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia. European Journal of Cancer, Supplement, 2007, 5, 13-22.	2.2	20
192	A stochastic model of susceptibility to antibiotic therapy—The effects of cross-resistance and treatment history. Artificial Intelligence in Medicine, 2007, 40, 57-63.	3.8	12
193	Sternal wound infection after coronary artery bypass graft surgery: Validation of existing risk scores. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 397-403.	0.4	69
194	Empirical Antifungal Therapy for Patients with Neutropenia and Persitent Fever - Systematic Review and Meta-Analysis Blood, 2007, 110, 4961-4961.	0.6	1
195	Immunoglobulin Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation - Systematic Review and Meta-Analysis Blood, 2007, 110, 4962-4962.	0.6	0
196	Comparison between Intravenous Iron and Oral Iron Preparations for the Treatment of Anemia of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. Blood, 2007, 110, 3748-3748.	0.6	1
197	Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2006, 59, 5-22.	1.3	115
198	Benefit of Appropriate Empirical Antibiotic Treatment: Thirty-day Mortality and Duration of Hospital Stay. American Journal of Medicine, 2006, 119, 970-976.	0.6	168

#	Article	IF	CITATIONS
199	Antibiotic prophylaxis in neutropenic patients. Cancer, 2006, 107, 1743-1751.	2.0	185
200	Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. Journal of Antimicrobial Chemotherapy, 2006, 58, 1238-1245.	1.3	181
201	Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2006, 57, 176-189.	1.3	182
202	Comment on Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. Journal of Antimicrobial Chemotherapy, 2006, 58, 220-220.	1.3	9
203	Prediction of Bacteremia Using TREAT, a Computerized Decision-Support System. Clinical Infectious Diseases, 2006, 42, 1274-1282.	2.9	71
204	Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2005, 55, 436-444.	1.3	96
205	Systematic Reviews and Meta-analysis of Febrile Neutropenia. Mayo Clinic Proceedings, 2005, 80, 1122-1125.	1.4	14
206	Three-day vs longer duration of antibiotic treatment for cystitis in women: Systematic review and meta-analysis. American Journal of Medicine, 2005, 118, 1196-1207.	0.6	85
207	Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. Journal of Antimicrobial Chemotherapy, 2004, 54, 29-37.	1.3	74
208	Considering resistance in systematic reviews of antibiotic treatment. Journal of Antimicrobial Chemotherapy, 2003, 52, 564-571.	1.3	11
209	Co-trimoxazole–Sensitive, Methicillin-Resistant <i>Staphylococcus aureus</i> , Israel, 1988–1997. Emerging Infectious Diseases, 2003, 9, 1168-1169.	2.0	23
210	Excess mortality in women with hospital-acquired bloodstream infection. American Journal of Medicine, 2001, 111, 120-125.	0.6	17
211	Bacteremic Pneumococcal Pneumonia. Clinical Infectious Diseases, 0, , .	2.9	0